Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.64 |
| ▸ | DRD4 | P21917 | 7/20 | 0.64 |
| ▸ | DRD3 | P35462 | 6/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968181 | 0.80 | DRD2 (0.73) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL6694944 | 0.80 | DRD2 (0.57) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL6701280 | 0.78 | DRD4 (0.75) | DRD2DRD4DRD3ADRA2CGAA | |
| SCHEMBL4519472 | 0.76 | DRD4 (0.62) | DRD2DRD4DRD3ADRA2CKEAP1 | |
| SCHEMBL23152040 | 0.75 | ADRA2C (0.79) | DRD2DRD3ADRA2CKEAP1GAA | |
| SCHEMBL11775877 | 0.75 | ADRA2C (0.79) | DRD2DRD3ADRA2CKEAP1GAA | |
| SCHEMBL7682702 | 0.73 | DRD2 (0.64) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL17764863 | 0.73 | ADRA2C (0.65) | DRD2DRD3ADRA2CKEAP1GAA | |
| SCHEMBL6701676 | 0.72 | DRD4 (0.55) | DRD2DRD4DRD3ADRA2CKMT2A | |
| SCHEMBL28770942 | 0.72 | DRD2 (0.62) | DRD2DRD4DRD3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | DRD2 4278/4885DRD4 4206/4885DRD3 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.